# Sildenafil for Microvasculopathy in Chronic TBI

> **NCT05782244** · PHASE2 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 160 (estimated)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Sildenafil Citrate low dose
- **DRUG:** Placebo
- **DRUG:** Sildenafil medium dose
- **DRUG:** Sildenafil high dose

## Key facts

- **NCT ID:** NCT05782244
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-02
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05782244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05782244, "Sildenafil for Microvasculopathy in Chronic TBI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05782244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*